These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19475451)

  • 41. Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer.
    Spiegelberg J; Neeff H; Holzner P; Runkel M; Fichtner-Feigl S; Glatz T
    World J Gastrointest Oncol; 2020 Aug; 12(8):903-917. PubMed ID: 32879667
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Melphalan: a promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Sardi A; Jimenez W; Nieroda C; Sittig M; Shankar S; Gushchin V
    Ann Surg Oncol; 2014 Mar; 21(3):908-14. PubMed ID: 24276642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pancytopenia after administration of hyperthermic intraperitoneal chemotherapy with mitomycin-C: local therapy and systemic toxicity.
    Wu V; Shen J; Chung SY; Saif MW
    Anticancer Drugs; 2021 Sep; 32(8):894-896. PubMed ID: 34145180
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I trial of thermal sensitization using induced oxidative stress in the context of HIPEC.
    Harrison LE; Tiesi G; Razavi R; Wang CC
    Ann Surg Oncol; 2013 Jun; 20(6):1843-50. PubMed ID: 23354567
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oncologic Risk Stratification Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Carcinomatosis.
    Wagner PL; Austin F; Zenati M; Jaech A; Mavanur A; Ramalingam L; Jones HL; Holtzman MP; Ahrendt SA; Zureikat AH; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2016 May; 23(5):1587-93. PubMed ID: 26744106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study.
    Jost E; Mack LA; Sideris L; Dube P; Temple W; Bouchard-Fortier A
    Can J Surg; 2020 Feb; 63(1):E71-E79. PubMed ID: 32080999
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
    Leung V; Huo YR; Liauw W; Morris DL
    Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
    Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
    Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peritoneal Surface Disease Severity Score as a predictor of resectability in the treatment of peritoneal surface malignancies.
    Yoon W; Alame A; Berri R
    Am J Surg; 2014 Mar; 207(3):403-7; discussion 406-7. PubMed ID: 24444858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early postoperative intraperitoneal chemotherapy is associated with survival benefit for appendiceal adenocarcinoma with peritoneal dissemination.
    Huang Y; Alzahrani NA; Liauw W; Soudy H; Alzahrani AM; Morris DL
    Eur J Surg Oncol; 2017 Dec; 43(12):2292-2298. PubMed ID: 29017824
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
    Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
    Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repeat Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy and Peritoneal Carcinomatosis.
    Wong JF; Tan GH; Wang W; Soo KC; Teo MC
    World J Surg; 2015 Jun; 39(6):1578-83. PubMed ID: 25651962
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colorectal cancer with peritoneal carcinomatosis: Clinical outcomes at 2 tertiary referral centers in Korea.
    Park EJ; Baik SH; Hur H; Min BS; Kang J; Han YD; Cho MS; Lee KY; Kim NK
    Medicine (Baltimore); 2017 May; 96(21):e6632. PubMed ID: 28538365
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
    Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
    Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei.
    Sørensen O; Andersen AM; Larsen SG; Giercksky KE; Flatmark K
    Clin Exp Metastasis; 2019 Dec; 36(6):511-518. PubMed ID: 31541325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.